These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2604981)

  • 41. Rescue factor: a design for evaluating long-acting analgesics.
    Savarese JJ; Thomas GB; Homesley H; Hill CS
    Clin Pharmacol Ther; 1988 Apr; 43(4):376-80. PubMed ID: 3356081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration.
    Breda M; Bianchi M; Ripamonti C; Zecca E; Ventafridda V; Panerai AE
    Int J Clin Pharmacol Res; 1991; 11(2):93-7. PubMed ID: 1879993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term therapy of tumor pain using morphine-retard tablets].
    Sorge J; Lehmkuhl C; Lohse K; Herrmann H; Pichlmayr I
    Med Klin (Munich); 1990 Sep; 85(9):523-8. PubMed ID: 2233610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer.
    Walsh TD; MacDonald N; Bruera E; Shepard KV; Michaud M; Zanes R
    Am J Clin Oncol; 1992 Jun; 15(3):268-72. PubMed ID: 1590284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Respiratory depression following controlled-release morphine sulfate tablets].
    Hoogslag PA; van Dijk B; Vinks AA
    Ned Tijdschr Geneeskd; 1989 Mar; 133(10):516-7. PubMed ID: 2710234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recovery of morphine from a controlled-release preparation. A source of opioid abuse.
    Crews JC; Denson DD
    Cancer; 1990 Dec; 66(12):2642-4. PubMed ID: 2249204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain.
    Boureau F; Saudubray F; d'Arnoux C; Vedrenne J; Estève M; Roquefeuil B; Siou DK; Brunet R; Ranchère JY; Roussel P
    J Pain Symptom Manage; 1992 Oct; 7(7):393-9. PubMed ID: 1484192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guidelines for use of controlled-release oral morphine in cancer pain management. Correlation with clinical experience.
    Lapin J; Portenoy RK; Coyle N; Houde RW; Foley KM
    Cancer Nurs; 1989 Aug; 12(4):202-8. PubMed ID: 2766263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Roles of outpatient nurses in the care of cancer patients receiving MS Contin tablets].
    Naito A; Sekiya Y
    Gan To Kagaku Ryoho; 1999 Dec; 26 Suppl 2():354-7. PubMed ID: 10630247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of controlled release morphine sulfate (MS Contin) in Queensland 1990-1993.
    Arnold P
    Med J Aust; 1995 Nov; 163(10):559. PubMed ID: 8538536
    [No Abstract]   [Full Text] [Related]  

  • 51. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.
    Portenoy RK; Sciberras A; Eliot L; Loewen G; Butler J; Devane J
    J Pain Symptom Manage; 2002 Apr; 23(4):292-300. PubMed ID: 11997198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Morphine for cancer pain.
    Glavina MJ
    N Z Med J; 1991 Jan; 104(904):6-7. PubMed ID: 2008261
    [No Abstract]   [Full Text] [Related]  

  • 53. Control of cancer-related pain with MS Contin: a comparison between 12-hourly and 8-hourly administration.
    Mignault GG; Latreille J; Viguié F; Richer P; Lemire F; Harsanyi Z; Stewart JH
    J Pain Symptom Manage; 1995 Aug; 10(6):416-22. PubMed ID: 7561223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine.
    Payne R; Mathias SD; Pasta DJ; Wanke LA; Williams R; Mahmoud R
    J Clin Oncol; 1998 Apr; 16(4):1588-93. PubMed ID: 9552070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer pain management and rectal opioids.
    Rousseau P
    South Med J; 1997 Mar; 90(3):365-6. PubMed ID: 9076317
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.
    Hagen NA; Thirlwell M; Eisenhoffer J; Quigley P; Harsanyi Z; Darke A
    J Pain Symptom Manage; 2005 Jan; 29(1):80-90. PubMed ID: 15652441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between plasma concentration of morphine and analgesic effectiveness.
    Yokokawa N; Hiraga K; Oguma T; Konishi M
    Postgrad Med J; 1991; 67 Suppl 2():S50-4. PubMed ID: 1758816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rectal, buccal, and sublingual narcotics for the management of cancer pain.
    Ripamonti C; Bruera E
    J Palliat Care; 1991; 7(1):30-5. PubMed ID: 2045992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bioavailability of morphine in rabbits after rectal administration of suppository containing controlled release morphine tablet.
    Kanamoto I; Zheng NX; Ueno M; Koizumi T; Adachi I; Horikoshi I
    Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1883-6. PubMed ID: 1394709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
    Clemens KE; Klaschik E
    Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.